A Better Newspaper

## Overview A growing number of families are pursuing lawsuits against major baby formula manufacturers, alleging that premature infants who consumed Similac or Enfamil developed necrotizing enterocolitis (NEC) (Top Class Actions, undated). ## Key Details - Families with premature infants diagnosed with NEC after consuming Similac or Enfamil are filing lawsuits and being invited to determine if they qualify for claims (Top Class Actions, undated). - The litigation is described as "growing," indicating an expanding docket of claims against these manufacturers (Top Class Actions, undated). ## Why It Matters This is part of a significant and growing mass tort involving major infant formula manufacturers (Abbott/Similac, Reckitt/Enfamil), with parallel litigation already tracked against Abbott Laboratories and ByHeart. The NEC formula litigation has become one of the largest active mass tort dockets in the US, with implications for pharmaceutical/consumer products liability law, MDL consolidation strategy, and potential multi-billion-dollar settlement exposure for manufacturers. ## Related Litigation Landscape - Abbott Laboratories – Preterm Infant Formula Litigation (existing tracked page) - ByHeart Infant Formula MDL Consolidation (existing tracked page) - This page tracks the broader NEC-specific claims wave spanning both Similac and Enfamil products, which may eventually intersect with MDL proceedings. ## Open Questions - Whether Similac and Enfamil litigation will be consolidated into existing or new MDLs. - Scientific and causation disputes likely to be central to bellwether trials. - Potential settlement scale given the volume of claims reported.